MYL12A: A Potential Drug Target for Myosin-Related Diseases (G10627)

Target Name: MYL12A

NCBI ID: G10627

MYL12A

MYL12A: A Potential Drug Target for Myosin-Related Diseases

Myosin is a protein that plays a crucial role in muscle function and growth. It is a key regulator of muscle contraction and relaxation, and is involved in many diseases, including muscular dystrophy, myopathies, and myofibrosis. Light polypeptide (MYL12A) is a regulatory protein that can interact with myosin and regulate its activity. MYL12A is non-sarcomeric, which means it does not have a well-defined sarcomere structure, and it is a potential drug target or biomarker.

The Importance of Myosin

Myosin is a protein that is composed of four polypeptide chains. It consists of a heavy chain, a light chain, a B-type domain, and a N-terminus. The heavy chain consists of 20kDa, while the light chain consists of 18kDa. The B-type domain is responsible for the interaction with myosin ATPase, which is a protein that generates ATP from ADP. The N-terminus is the site of the protein-protein interaction between myosin and other proteins.

Myosin plays a crucial role in muscle function and growth. It is involved in the regulation of muscle contraction and relaxation, as well as in the maintenance of muscle structure and integrity. Myosin is also involved in many diseases, including muscular dystrophy, myopathies, and myofibrosis.

MYL12A: A Potential Drug Target

MYL12A is a non-sarcomeric protein that can interact with myosin. It has been shown to regulate myosin ATPase activity and to play a role in the regulation of muscle contraction. Therefore, MYL12A is a potential drug target or biomarker for diseases that are caused by the disruption of myosin function.

MYL12A has been shown to interact with several myosin ATPase subunits, including the alpha-subunit, beta-subunit, and gamma-subunit. These interactions may modulate the activity of the ATPase and affect the regulation of muscle contraction.

MYL12A has also been shown to play a role in the regulation of muscle fiber type and myofibrosis. It has been shown to promote the proliferation and migration of myofibroblasts, which are the cells that cause myofibrosis. This may contribute to the development of myofibrosis-related diseases.

MYL12A has also been shown to play a role in the regulation of muscle protein synthesis. It has been shown to enhance the translation of myosin light chain protein (MLA) into myosin protein, which is involved in muscle contraction. This may contribute to the regulation of muscle contraction and the maintenance of muscle structure.

Conclusion

MYL12A is a non-sarcomeric protein that can interact with myosin. It has been shown to regulate myosin ATPase activity and to play a role in the regulation of muscle contraction, myofibrosis, and muscle protein synthesis. Therefore, MYL12A is a potential drug target or biomarker for diseases that are caused by the disruption of myosin function. Further research is needed to fully understand the role of MYL12A in muscle function and disease.

Protein Name: Myosin Light Chain 12A

Functions: Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Implicated in cytokinesis, receptor capping, and cell locomotion (By similarity)

The "MYL12A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYL12A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets